EP Patent

EP2161030A1 — Oxytocin formulations and uses thereof

Assigned to Rijksuniversiteit Groningen · Expires 2010-03-10 · 16y expired

What this patent protects

The present invention relates to the field of preventive and therapeutic medicine, in particular, oxytocin formulations. Provided is an aqueous oxytocin formulation comprising oxytocin or a functional analogue thereof, and a non-toxic source of metal ions, and the use of the form…

USPTO Abstract

The present invention relates to the field of preventive and therapeutic medicine, in particular, oxytocin formulations. Provided is an aqueous oxytocin formulation comprising oxytocin or a functional analogue thereof, and a non-toxic source of metal ions, and the use of the formulation for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of haemorrhage. Also, provided is a method for treating or preventing haemorrhage in a subject in need thereof, comprising administering to said subject an effective dosage amount of a formulation according to the invention.

Drugs covered by this patent

Patent Metadata

Patent number
EP2161030A1
Jurisdiction
EP
Classification
Expires
2010-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Rijksuniversiteit Groningen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.